Teichman 2006 — CJC-1295 Phase 1

J Clin Endocrinol Metab·March 1, 2006

Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman

Summary

Single CJC-1295 injection produced dose-dependent GH increases (2-10 fold for ≥6 days) and IGF-I increases (1.5-3 fold for 9-11 days). Half-life was 5.8-8.1 days.

Study Details

Study Design

Two randomized, placebo-controlled, double-blind, ascending dose trials

Indication

Healthy volunteers

Intervention

CJC-1295 SC

Species

Human

Sample Size

12 subjects

Risk of Bias Assessment

ConjuChem-sponsored